DUBLIN, Feb. 19, 2020 /CNW/ -- Endo International
plc (NASDAQ: ENDP) today announced that its Board of Directors has
appointed Mark G. Barberio to serve
as a director, effective February 19,
2020. Mr. Barberio has also been appointed to Endo's Audit
and Nominating & Governance Committees.
Mr. Barberio is the principal of Markapital, LLC, a business and
merger & acquisition consulting firm. Prior to founding
Markapital, he led Mark IV, LLC (now Dayco, LLC), a global
diversified manufacturing company, where he served in a number of
leadership positions, including as its Co-Chief Executive Officer
and Chief Financial Officer.
"In addition to Mark's senior executive leadership experience,
Mark's operations, finance and strategic planning perspective on
corporate growth will provide valuable insight to the Board,"
said Paul Campanelli, Endo's Chairman, President and Chief
Executive Officer. "We are pleased to welcome him to our
Board."
Separately, Endo announced today that Blaise Coleman will succeed Paul Campanelli as President and Chief Executive
Officer and become a member of the Board of Directors effective
March 6, 2020. Mr. Barberio becomes
the sixth independent director on Endo's eight member Board, which
also reflects the addition of Mr. Coleman.
About Endo International plc
Endo International plc (NASDAQ: ENDP) is a highly focused
generics and specialty branded pharmaceutical company delivering
quality medicines to patients in need through excellence in
development, manufacturing and commercialization. Endo has global
headquarters in Dublin, Ireland,
and U.S. headquarters in Malvern,
PA. Learn more at www.endo.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains certain forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995 and the relevant Canadian securities legislation,
including, but not limited to, the statements by Mr. Campanelli and
other statements regarding changes to the Board of Directors.
Statements including words such as "believes," "expects,"
"anticipates," "intends," "estimates," "plan," "will," "may," "look
forward," "intend," "guidance," "future" or similar expressions are
forward-looking statements. Because these statements reflect Endo's
current views, expectations and beliefs concerning future events,
they involve risks and uncertainties. Although Endo believes that
these forward-looking statements and information are based upon
reasonable assumptions and expectations, readers should not place
undue reliance on them, or any other forward-looking statements or
information in this news release. Investors should note that many
factors, as more fully described in the documents filed by Endo
with the Securities and Exchange Commission and with securities
regulators in Canada on the System
for Electronic Document Analysis and Retrieval, including under the
caption "Risk Factors" in Endo's Form 10-K, Form 10-Q and Form 8-K
filings, and as otherwise enumerated herein or therein, could
affect Endo's future results and could cause Endo's actual results
to differ materially from those expressed in forward-looking
statements contained in this communication. The forward-looking
statements in this press release are qualified by these risk
factors. Endo assumes no obligation to publicly update any
forward-looking statements, whether as a result of new information,
future developments or otherwise, except as may be required under
applicable securities laws.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/endo-appoints-mark-g-barberio-to-board-of-directors-301007700.html
SOURCE Endo International plc